An HIV-1 clade a/E DNA prime, recombinant fowlpox virus boost vaccine is safe, but non-immunogenic in a randomized phase 1/11a trial in Thai volunteers at low risk of HIV infection

Human Vaccines

Volumn 6, Issue 10, 2010, Pages 835-840

  Hemachandra, Atchriya ^a   Puls, Rebekah L ^b   Sirivichayakul, Sunee ^c   Kerr, Stephen ^a,b   Thantiworasit, Pattarawat ^c   Ubolyam, Sasiwimol ^a   Cooper, David A ^b,d   Emery, Sean ^b   Phanuphak, Praphan ^a   Kelleher, Anthony ^b,d   Ruxrungtham, Kiat ^a,c,e  

^a THAI RED CROSS AIDS RESEARCH CENTRE   (Thailand)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c CHULALONGKORN UNIVERSITY   (Thailand)

^d ST VINCENT S HOSPITAL   (Australia)

^e CHULALONGKORN UNIVERSITY   (Thailand)

Author keywords

AIDS vaccine; Clinical trial; DNA fowlpox; HIV; Thailand

Indexed keywords

AE CLADE DNA VACCINE; AE CLADE RECOMBINANT FOWLPOX HIV VACCINE; DNA VACCINE; GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTHENIA; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILL; CLADISTICS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOUBLE BLIND PROCEDURE; DRUG SAFETY; ENVELOPE GENE; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; FOWLPOX VIRUS; GROUP SPECIFIC ANTIGEN GENE; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOGENICITY; INJECTION SITE PAIN; MALE; MYALGIA; NAUSEA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; REGULATOR GENE; STRUCTURAL GENE; THAILAND; UPPER RESPIRATORY TRACT INFECTION; VACCINATION; VOLUNTEER;

ADULT; AIDS VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYTOKINES; DOUBLE-BLIND METHOD; DRUG CARRIERS; FEMALE; FOWLPOX VIRUS; GENETIC VECTORS; HIV INFECTIONS; HIV-1; HUMAN EXPERIMENTATION; HUMANS; IMMUNIZATION; IMMUNIZATION, SECONDARY; INJECTIONS, INTRAMUSCULAR; MALE; MIDDLE AGED; PLACEBOS; THAILAND; VACCINES, DNA; VACCINES, SUBUNIT; VACCINES, SYNTHETIC;

EID: 78649336269     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.6.10.12635     Document Type: Article

References (35)

1. Ruxrungtham K, Brown T, Phanuphak P. HIV/AIDS in Asia. Lancet 2004; 364:69-82.
2. UNGASS Country Progress Report: Thailand, National AIDS Prevention and Alleviation Committee. National Plan for the Prevention and Alleviation of AIDS in Thailand 2008.
3. Brown T, Peerapatanapokin W. For the Thai Working Group on HIV/AIDS Projection. Projections for HIV/AIDS in Thailand: 2000-2020, Division of AIDS, Department of Disease Control, Ministry of Public Health, Bangkok 2001.
4. van Griensven F, Thanprasertsuk S, Jommaroeng R, Mansergh G, Naorat S, Jenkins RA, et al. Evidence of a previously undocumented epidemic of HIV infection among men who have sex with men in Bangkok, Thailand. AIDS 2005; 19:521-6.
5. Mason CJ, Kitsiripornchai S, Markowitz LE, Chanbancherd P, Supapongse T, Jugsudee A, et al. Nationwide surveillance of HIV-1 prevalence and subtype in young Thai men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 19:165-73. (Pubitemid 28460691)
6. Ruxrungtham K, Phanuphak P. Update on HIV/AIDS in Thailand. J Med Assoc Thai 2001; 84:1-17.
7. Weniger BG, Takebe Y, Ou CY, Yamazaki S. The molecular epidemiology of HIV in Asia. AIDS 1994; 82:13-28.
8. Karnasuta C, Paris RM, Cox JH, Nitayaphan S, Pitisuttithum P, Thongcharoen P, et al. Antibody-dependent cell-mediated cytotoxic responses in participants enrolled in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 2005; 23:2522-9.
9. Nitayaphan S, Pitisuttithum P, Karnasuta C, Eamsila C, de Souza M, Morgan P, et al. Safety and immunogenicity of an HIV subtype B and E prime-boost vaccine combination in HIV-negative Thai adults. J Infect Dis 2004; 190:702-6.
10. Pitisuttithum P, Nitayaphan S, Thongcharoen P, Khamboonruang C, Kim J, de Souza M, et al. Safety and immunogenicity of combinations of recombinant subtype E and B human immunodeficiency virus type 1 envelope glycoprotein 120 vaccines in healthy Thai adults. J Infect Dis 2003; 188:219-27. (Pubitemid 36898153)
11. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, van Grievsen MH, Hu D, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006; 194:1661-71.
12. Thongcharoen P, Suriyanon V, Paris RM, Khamboonruang C, de Souza MS, Ratto-Kim S, et al. A phase 1/2 comparative vaccine trial of the safety and immunogenicity of a CRF01-AE (subtype E) candidate vaccine: ALVAC-HIV (vCP1521) prime with oligomeric gp160 (92TH023/LAI-DID) or bivalent gp120 (CM235/SF2) boost. J Acquir Immune Defic Syndr 2007; 46:48-55.
13. Clerici M, Berzofsky JA, Shearer GM, Tacket CO. Exposure to human immunodeficiency virus (HIV) type I indicated by HIV-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies. J Infect Dis 1991; 164:178-82.
14. Clerici M, Giorgi JV, Chou CC, Gudeman VK, Zack JA, Gupta P, et al. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1. J Infect Dis 1992; 165:1012-9.
15. Kaul R, Rowland-Jones SL, Kimani J, Dong T, Yang HB, Kiama P, et al. Late seroconversion in HIV-resistant Nairobi prostitutes despite pre-existing HIV-specific CD8+ responses. J Clin Invest 2001; 107:341-9. (Pubitemid 32157966)
16. + T cells in HIV infection. Philos Trans R Soc Lond B Biol Sci 2000; 355:363-7.
17. Pantaleo G, Koup RA. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004; 10:806-10.
18. Rowland-Jones S, Sutton J, Ariyoshi K, Dong T, Gotch F, McAdam S, et al. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women. Nat Med 1995; 1:59-64.
19. Kelleher AD, Puls RL, Bebbington M, Boyle D, Ffrench R, Kent SJ, et al. A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. AIDS 2006; 20:294-7.
20. De Rose R, Chea S, Dale CJ, Reece J, Fernandez CS, Wilson KM, et al. Subtype AE HIV-1 DNA and recombinant fowlpoxvirus vaccines encoding five shared HIV-1 genes: safety and T cell immunogenicity in macaques. Vaccine 2005; 23:1949-56.
21. De Rose R, Batten CJ, Smith MZ, Fernandez CS, Peut V, Thomson S, et al. Comparative efficacy of subtype AE simian-human immunodeficiency virus priming and boosting vaccines in pigtail macaques. J Virol 2007; 81:292-300. (Pubitemid 44975169)
22. Boyle DB, Anderson MA, Amos R, Voysey R, Coupar BE. Construction of recombinant fowlpox viruses carrying multiple vaccine antigens and immunomodulatory molecules. Biotechniques 2004; 37:104-6.
23. Coupar BE, Purcell DF, Thomson SA, Croom HA, Thomson S, Coupar BE, et al. Fowlpox virus vaccines for HIV and SHIV clinical and pre-clinical trials. Vaccine 2006; 24:1378-88.
24. Dale CJ, De Rose R, Wilson KM, Croom HA, Thomson S, Coupar BE, et al. Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFNgamma or IL-12. Vaccine 2004; 23:188-97. (Pubitemid 39505088)
25. De Rose R, Sullivan MT, Dale CJ, Kelleher AD, Emery S, Cooper DA, et al. Dose-response relationship of DNA and recombinant fowlpox virus prime-boost HIV vaccines: implications for future trials. Hum Vaccin 2006; 2:134-6.
26. Dubey S, Clair J, Fu TM, Guan L, Long R, Mogg R, et al. Detection of HIV vaccine-induced cell-mediated immunity in HIV-seronegative clinical trial participants using an optimized and validated enzyme-linked immunospot assay. J Acquir Immune Defic Syndr 2007; 45:20-7.
27. Buchbinder SP, Mehrotra DV, Duerr A, Fitzgerald DW, Mogg R, Li D, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372:1881-93.
28. McElrath MJ, De Rosa SC, Moodie Z, Dubey S, Kierstead L, Janes H, et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008; 372:1894-905.
29. Graham BS, Koup RA, Roederer M, Bailer RT, Enama ME, Moodie Z, et al for the Vaccine Research Center 004 Study Team. Phase 1 safety and immunogenicity evaluation of a multiclade HIV-1 DNA candidate vaccine. J Infect Dis 2006; 194:1650-60.
30. McConkey SJ, Reece WH, Moorthy VS, Webster D, Dunachie S, Butcher G, et al. Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans. Nat Med 2003; 9:729-35. (Pubitemid 36749222)
31. Walther M, Thompson FM, Dunachie S, Keating S, Todryk S, Berthoud T, et al. Safety, immunogenicity and efficacy of prime-boost immunization with recombinant poxvirus FP9 and modified vaccinia virus Ankara encoding the full-length Plasmodium falciparum circumsporozoite protein. Infect Immun 2006; 74:2706-16.
32. Webster DP, Dunachie S, McConkey S, Poulton I, Moore AC, Walther M, et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine 2006; 24:3026-34.
33. Cottingham MG, van Maurik A, Zago M, Newton AT, Anderson RJ, Howard MK, et al. Different levels of immunogenicity of two strains of fowlpox virus as recombinant vaccine vectors eliciting T-cell responses in heterologous prime-boost vaccination strategies. Clin Vaccine Immunol 2006; 13:747-57.
34. Luckay A, Sidhu MK, Kjeken R, Megati S, Chong SY, Roopchand V, et al. Effect of plasmid DNA vaccine design and in vivo electroporation on the resulting vaccine-specific immune responses in rhesus macaques. J Virol 2007; 81:5257-69.
35. Kim CY, Kang ES, Kim SB, Kim HE, Choi JH, Lee DS, et al. Increased in vivo immunological potency of HB-110, a novel therapeutic HBV DNA vaccine, by electroporation. Exp Mol Med 2008; 40:669-76.